Klemens Egger
Postdoctoral Scientist
Data updated
Research Footprint
Klemens Egger appears in 5 tracked papers (2024–2026), most studied alongside Ayahuasca, DMT and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Medicinal Chemistry & Drug Development.
Most-cited paper: Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat (14 citations).
Frequent co-authors: Milan Scheidegger, John Smallridge and Dominik Dornbierer.
Background & Research
Klemens Egger is a neuroscientist and postdoctoral scientist at the University of Zurich/University Hospital of Psychiatry Zurich. His research focuses on the pharmacology and neurobiology of DMT and harmine, including human clinical studies, fMRI, and FDG-PET investigations. He trained in chemistry and biomedical neuroscience, and his PhD work centered on psychedelic neuroimaging and drug interactions.
Key Impact
Notable for leading and coauthoring multiple high-profile human and translational studies on DMT and harmine, spanning pharmacokinetics, neuroimaging, and brain metabolism.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Klemens Egger's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.